The aim of our study was to evaluate the efficacy and safety of the MEK inhibitor, trametinib, at its licensed dose in other malignancies, compared with physician's choice standard of care in women with recurrent low-grade serous carcinoma. The gene discussed is MAP2K7; the disease is serous adenocarcinoma.